Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MOH To Inaugurate National Basic Medicine System In 2009

This article was originally published in PharmAsia News

Executive Summary

At the Seventh World Congress on Health Economics, the Department of Planning and Finance under China's Ministry of Health disclosed that the national basic medicine system will be implemented nationwide this year. MOH will formulate and issue the national basic medicine catalog (2009 edition), which includes more than 300 Western medicines and 300 TCMs. The agency proposes cancelling the adjustment fee for basic medicines, starting with all pilot health care institutions and basic level hospitals such as rural and community hospitals. This will be defined more clearly in the health care reform plan. Public hospital reform will depend on government subsidies: if public financing provides full subsidies, drug dispensing fees will not be imposed nor medical service charges raised. (Click here for more - Chinese Language)

You may also be interested in...

Giddy Emphasizes Shape To Differentiate Its OTC ED Device In Crowded And Growing Market

Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.

How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Brexit: Life Science Firms In An ‘Impossible Position’

As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts